Reduced health care expenditures after enrollment in a collaborative cardiac care service

Pharmacotherapy

Volumn 30, Issue 11, 2010, Pages 1127-1135

  Delate, Thomas ^a   Olson, Kari L ^a,b,c   Rasmussen, Jon ^a,b,c   Hutka, Kara ^a,b,c   Sandhoff, Brian ^a,b,c   Hornak, Roseanne ^a,b,c   Merenich, John ^b,d  

^a Pharmacy Department   (United States)

^b Clinical Pharmacy Cardiac Risk Service   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Clinical Informatics Decision Support   (United States)

Author keywords

Coronary artery disease; Disease management; Health expenditures; Pharmacists

Indexed keywords

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR RISK; COLLABORATIVE CARDIAC CARE SERVICE; CONTROLLED STUDY; CORONARY STENT; COST CONTROL; COST UTILITY ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; RISK REDUCTION; SEX DIFFERENCE;

ACUTE DISEASE; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; COLORADO; COOPERATIVE BEHAVIOR; CORONARY ARTERY DISEASE; COST CONTROL; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; FOLLOW-UP STUDIES; HEALTH EXPENDITURES; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 78149301184     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.11.1127     Document Type: Article

References (24)

1. LaBresh KA, Gliklich R, Liljestrand J, Peto R, Ellrodt AG. Using "get with the guidelines" to improve cardiovascular secondary prevention. Jt Comm J Qual Saf 2003;29:539-50.
2. McAlister FA, Lawson ME, Teo KK, Armstrong PW. Randomized trials of secondary prevention programmes in coronary disease: systematic review. BMJ 2001;323:957-62.
3. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
4. Merenich J, Olson KL, Delate T, Rasmussen J, Helling DK, Ward DC, for the Clinical Pharmacy Cardiac Risk Service Study Group. Mortality reduction benefits of a comprehensive cardiac care program for patients with occlusive coronary artery disease. Pharmacotherapy 2007;27:1370-8. (Pubitemid 47530443)
5. Scott A, Tinelli M, Bond C. Costs of a community pharmacist-led medicines management service for patients with coronary heart disease in England: healthcare system and patient perspectives. Pharmacoeconomics 2007;25:397-411.
6. Hilleman DE, Faulkner MA, Monaghan MS. Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia. Pharmacotherapy 2004;24;1077-83.
7. DiTusa L, Luzier AB, Brady G, Reinhardt M, Snyder BD. A pharmacy-based approach to cholesterol management. Am J Manag Care 2001;7:973-9.
8. Perez A, Doloresco F, Hoffman JM, et al. Economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy 2008;28:285e-323.
9. Sandhoff BG, Nies LK, Olson KL, Nash JD, Rasmussen JR, Merenich JA. Clinical pharmacy cardiac risk service: guidelines and practices in a population approach to managing patients with coronary artery disease. Am J Health-Syst Pharm 2007;64:77-84.
10. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995;33:783-95.
11. Olson KL, Rasmussen J, Sandhoff BJ, Merenich JA. A global and sustained approach to lipid management of 8,014 patients with coronary artery disease: the 5-year Colorado Kaiser Permanente clinical pharmacy cardiac risk service (CPCRS) experience. Arch Intern Med 2005;165:49-54.
12. Helling DK, Nelson KM, Ramirez JE, Humphries TL. Kaiser Permanente Colorado region pharmacy department: innovative leader in pharmacy practice. J Am Pharm Assoc 2006;46:67-76.
13. Bergstralh EJ, Kosanke JL. Computerized matching of controls. Technical report number 56. April 1995. Available from http://mayoresearch.mayo.edu/ biostat/upload/56.pdf. Accessed April 21, 2010.
14. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
15. Otani K, Baden WW. Healthcare cost and predictive factors: high- and low-utilization model development. Health Market Q 2009;26;198-208.
16. Raebel MA, Malone DC, Conner DA, Xu S, Porter JA, Lanty FA. Health services use and health care costs of obese and nonobese individuals. Arch Intern Med 2004;164:2135-40. (Pubitemid 39410803)
17. Estabrooks PA, Shetterly S. The prevalence and health care use of overweight children in an integrated health care system. Arch Pediatr Adolesc Med 2007;161:222-7. (Pubitemid 46364325)
18. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
19. Qureshi AI, Suri FK, Guterman LR, Hopkins N. Ineffective secondary prevention in survivors of cardiovascular events in the US population. Arch Intern Med 2001;161:1621-8.
20. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-25.
21. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 2005;330:1059-63. (Pubitemid 40646559)
22. Krause DS. Economic effectiveness of disease management programs: a meta-analysis. Dis Manag 2005;8:114-34.
23. Athyros VG, Kakafika A, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins - clinical evidence. Curr Pharm Des 2009;15:479-89.
24. Bureau of Labor Statistics. Consumer price index. Available from www.http://www.bls.gov/cpi/tables.htm. Accessed April 21, 2010.